Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,275.00+4.44%ETH$2,409.90+6.50%GOLD$4,123.90+1.25%OIL$87.80-0.36%
Smart Investors Daily
SID Premium
CV

NASDAQ · CV

CapsoVision, Inc.

Healthcare · Medical - Equipment & Services

$6.70

Up+$0.15 (+2.24%)

Updated Nov 4, 2026, 11:59 PM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
674.03M
P/E ratio
-28.7
Dividend yield
0.00%
52-week range
$4.74 – $9.17
Volume
246.32K
Avg. volume
80.82K

Price performance · CV

CV price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

CV closed at $6.70 after 20 trading sessions, up 2.45% for the selected period.

Last close
$6.70
Period change
+2.45%
Period low
$6.45
Period high
$7.06
Daily close
View OHLC price history
CV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$6.79$6.865$6.36$6.70246.32K
Nov 2, 2026$6.91$7.03$6.70$6.73104.48K
Oct 30, 2026$6.99$7.10$6.79$6.8386.78K
Oct 29, 2026$7.10$7.23$6.89$6.94101.94K
Oct 28, 2026$6.78$7.13$6.77$7.06220.28K
Oct 27, 2026$6.94$6.98$6.71$6.75111.72K
Oct 26, 2026$7.00$7.09$6.63$6.89104.8K
Oct 23, 2026$6.72$7.18$6.66$6.99320.23K
Oct 22, 2026$6.75$6.80$6.73$6.80111.42K
Oct 21, 2026$6.73$6.80$6.67$6.80171.36K
Oct 20, 2026$6.70$6.78$6.68$6.6862.35K
Oct 19, 2026$6.53$6.74$6.48$6.6776.16K
Oct 16, 2026$6.46$6.65$6.40$6.53160.78K
Oct 15, 2026$6.69$6.75$6.24$6.45169.97K
Oct 14, 2026$6.74$6.79$6.615$6.6480.26K
Oct 13, 2026$6.76$6.8025$6.64$6.7886.81K
Oct 12, 2026$6.54$6.81$6.53$6.76107.25K
Oct 9, 2026$6.62$6.73$6.535$6.5957.97K
Oct 8, 2026$6.48$6.71$6.41$6.6291.39K
Oct 7, 2026$6.39$6.58$6.385$6.54104.53K

Latest CV news

The latest Smart Investors Daily articles mentioning CV.

Stock researchCompany · Overview

CV research

Overview

Company profile and research snapshot.

Company profile

CapsoVision Inc is a commercial-stage medical technology enterprise, innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. Internal GI imaging facilitates earlier detection of colorectal cancer and other diseases, enabling more timely and effective treatment regimens for patients. The Company's core technology platform is an orally ingestable capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. The Company's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D directed at the large intestines.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.00
Implied upside
—
Analysts
—
CV recent ratings
DateFirmRatingTarget
Mar 27, 2026BenchmarkSpeculative Buy—
Dec 31, 2025BenchmarkSpeculative Buy—
Jul 28, 2025BenchmarkSpeculative Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026

SARATOGA, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release third quarter 2026 financial results on Thursday, November 12, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a cor

Yahoo · Oct 24, 2026

CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening

CapsoVision (NASDAQ:CV) outlined its strategy to expand capsule endoscopy technology beyond its current small-bowel business into colon, pancreatic and esophageal cancer screening applications, highlighting its artificial intelligence capabilities, cloud-based workflow and upcoming regulatory submis

Yahoo · Oct 13, 2026

CapsoVision to Present at the 20th Annual LD Micro Main Event

SARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will present at the 20th Annual LD Micro Main Event, taking place October 19-21, 2026, at the Luxe Sunset Boulevard Hot

Yahoo · Sep 28, 2026

CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® systemSARATOGA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that AI Highlights™, its AI-assisted reading tool for the CapsoCam Plus system, received clearance from the U.S. Fo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By